Neurogene (NGNE) Short Interest Ratio & Short Volume $19.52 +1.53 (+8.50%) As of 05/19/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Neurogene Short Interest DataNeurogene (NGNE) has a short interest of 2.95 million shares, representing 25.13% of the float (the number of shares available for trading by the public). This marks a 3.15% increase in short interest from the previous month. The short interest ratio (days to cover) is 10.8, indicating that it would take 10.8 days of the average trading volume of 240,624 shares to cover all short positions.Current Short Interest2,950,000 sharesPrevious Short Interest2,860,000 sharesChange Vs. Previous Month+3.15%Dollar Volume Sold Short$44.25 millionShort Interest Ratio10.8 Days to CoverLast Record DateApril 30, 2025Outstanding Shares14,262,000 sharesFloat Size11,740,000 sharesShort Percent of Float25.13%Today's Trading Volume239,144 sharesAverage Trading Volume240,624 sharesToday's Volume Vs. Average99% Short Selling Neurogene? Sign up to receive the latest short interest report for Neurogene and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNGNE Short Interest Over TimeNGNE Days to Cover Over TimeNGNE Percentage of Float Shorted Over Time Neurogene Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20252,950,000 shares $44.25 million +3.2%25.1%10.8 $15.00 4/15/20252,860,000 shares $32.49 million +17.2%24.4%10.2 $11.36 3/31/20252,440,000 shares $28.57 million +11.9%19.9%9.2 $11.71 3/15/20252,180,000 shares $36.41 million +11.2%12.6%9.3 $16.70 2/28/20251,960,000 shares $34.67 million +12.0%11.3%8 $17.69 2/15/20251,750,000 shares $32.24 million -12.9%10.1%5.4 $18.42 1/31/20252,010,000 shares $31.86 million +10.4%11.4%4.8 $15.85 1/15/20251,820,000 shares $33.74 million No Change10.4%4.6 $18.54 12/31/20241,820,000 shares $41.61 million +13.8%11.3%4.8 $22.86 12/15/20241,600,000 shares $37.62 million +36.8%9.9%4.3 $23.51 Get the Latest News and Ratings for NGNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. 11/30/20241,170,000 shares $29.75 million -28.7%10.2%3.4 $25.43 11/15/20241,640,000 shares $56.60 million +79.4%14.2%5.4 $34.52 10/31/2024914,200 shares $40.23 million -2.2%8.9%6.8 $44.01 10/15/2024934,600 shares $46.70 million -50.8%9.1%8.2 $49.97 9/30/20241,900,000 shares $79.72 million +6.2%18.5%16.8 $41.96 9/15/20241,790,000 shares $75.09 million -1.7%17.4%13.7 $41.95 8/31/20241,820,000 shares $68.10 million +4.6%17.7%14.1 $37.42 8/15/20241,740,000 shares $61.98 million +11.5%16.9%13.6 $35.62 7/31/20241,560,000 shares $64.18 million +8.3%13.4%12.6 $41.14 7/15/20241,440,000 shares $66.17 million +34.6%12.4%12.4 $45.95 6/30/20241,070,000 shares $38.94 million +0.9%9.2%9.5 $36.39 6/15/20241,060,000 shares $45.15 million +8.5%9.1%10.1 $42.59 5/31/2024977,400 shares $36.75 million -2.0%8.4%7.8 $37.60 5/15/2024997,800 shares $33.52 million -2.2%8.6%7.5 $33.59 4/30/20241,020,000 shares $35.17 million +3.2%8.9%7.7 $34.48 4/15/2024988,100 shares $36.98 million +9.1%8.6%7.1 $37.43 3/31/2024906,000 shares $46.12 million +130.4%7.9%6.7 $50.90 3/15/2024393,200 shares $14.76 million +50.8%3.4%3.4 $37.53 2/29/2024260,700 shares $8.10 million +68.2%2.3%3.4 $31.07 2/15/2024155,000 shares $4.65 million +295.4%1.3%2.4 $30.00 1/31/202439,200 shares $1.18 million No Change0.4%0.8 $30.16 NGNE Short Interest - Frequently Asked Questions What is Neurogene's current short interest? Short interest is the volume of Neurogene shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 2,950,000 shares of NGNE short. 25.13% of Neurogene's shares are currently sold short. Learn More on Neurogene's current short interest. What is a good short interest ratio for Neurogene? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NGNE shares currently have a short interest ratio of 11.0. Learn More on Neurogene's short interest ratio. Which institutional investors are shorting Neurogene? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurogene: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Neurogene? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 25.13% of Neurogene's floating shares are currently sold short. Is Neurogene's short interest increasing or decreasing? Neurogene saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,950,000 shares, an increase of 3.1% from the previous total of 2,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Neurogene's float size? Neurogene currently has issued a total of 14,262,000 shares. Some of Neurogene's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Neurogene currently has a public float of 11,740,000 shares. How does Neurogene's short interest compare to its competitors? 25.13% of Neurogene's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Neurogene: Phibro Animal Health Co. (4.52%), Mineralys Therapeutics, Inc. (16.91%), Collegium Pharmaceutical, Inc. (14.75%), Syndax Pharmaceuticals, Inc. (25.17%), Arcus Biosciences, Inc. (12.18%), Enliven Therapeutics, Inc. (21.79%), Avadel Pharmaceuticals plc (10.54%), Spyre Therapeutics, Inc. (24.50%), Intellia Therapeutics, Inc. (27.76%), Pharvaris (3.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Neurogene stock? Short selling NGNE is an investing strategy that aims to generate trading profit from Neurogene as its price is falling. NGNE shares are trading up $1.53 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neurogene? A short squeeze for Neurogene occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NGNE, which in turn drives the price of the stock up even further. How often is Neurogene's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NGNE, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies PAHC Short Interest Data MLYS Short Interest Data COLL Short Interest Data SNDX Short Interest Data RCUS Short Interest Data ELVN Short Interest Data AVDL Short Interest Data SYRE Short Interest Data NTLA Short Interest Data PHVS Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NGNE) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s treachery A shocking bill has been put before the House of Representatives… Representative Brandon Gill wants Preside...Porter & Company | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.